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4.001
he spread of hypervirulent Clostridium difﬁcile PCR
ibotype 027 in Europe
.J. Kuijper1,∗, D.L. Monnet2
National Reference Laboratory for Clostridium difﬁcile,
eiden, Netherlands
European Centre for Disease Prevention and Control
ECDC), Stockholm, Sweden
ackground: Since 2002, increasing rates of Clostridium
ifﬁcile-associated infections (CDI) with a more severe
ourse, higher mortality and more complications have been
eported in Canada, USA and Europe. This increased viru-
ence is assumed to be associated with higher amounts of
oxin production by a strain belonging to PCR ribotype 027,
oxinotype III (Type 027).
Methods: Following the ﬁrst cases of C. difﬁcile Type
27 in Europe, a network of microbiologists and epidemi-
logists from national reference centers was established.
lostridium difﬁcile strains were sent to National Reference
aboratories for further investigations. The Reference labo-
atory in Leiden conﬁrmed most of the ﬁrst isolated Type
27 isolates in each country.
Results: As of April 2008, C. difﬁcile Type 027 was found
n 16 European member states and in Switzerland. Seven
ountries only reported sporadic cases of Type 027. Of these
countries, 2 countries reported on patients with infec-
ions acquired abroad in countries known to be affected
y Type 027. One country reported an outbreak with the
ndex patient having acquired PCR ribotype 027 during
tay in a foreign hospital. England and Wales, Belgium,
rance, Luxembourg, Finland and The Netherlands reported
high number of hospitals affected by Type 027. Applica-
ion of a recently developed Multi-Locus Variable Number
f Tandem Repeat Analysis (MLVA) for C. difﬁcile on iso-
ates from individual countries revealed speciﬁc subtypes
n some countries. Type 027 isolates were generally suscep-
ible to clindamycin and resistant to erythromycin, however
lindamycin-resistant, erythromycin-resistant, ErmB posi-
ive Type 027 strains have been found in Switzerland,
rance and Ireland. In contrast, erythromycin-susceptible,
lindamycin-susceptible strains were found in Denmark and
ermany. Information on the attributable mortality was
vailable from France (4%)and The Netherlands (4.1%). Sys-
ematic surveillance studies have been developed in all
ountries affected by Type 027, but they differ considerably
n design.Conclusions: C. difﬁcile PCR ribotype 027, toxinotype III
as been found in more than 250 hospitals in 17 countries
nd is rapidly spreading in Europe.
oi:10.1016/j.ijid.2008.05.098
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iagnosing Clostridium difﬁcile-Associated Diseases: The
tate of the Art
.E. Nord
Karolinska Institute, Stockholm, Sweden
lostridium difﬁcile can cause antibiotic-associated diar-
hea, colitis and pseudomembranous colitis, known as C.
ifﬁcile-associated diseases (CDAD). It has been reported
n the literature since the late 1970s, and outbreaks con-
inue to occur despite breakthroughs in laboratory diagnosis,
ffective treatments and infection control programs. Dur-
ng recent years the number of outbreaks of CDAD that are
evere has risen signiﬁcantly in many North American and
uropean hospitals.
Three virulence factors have been described in C. difﬁ-
ile strains: toxin A (TcdA), toxin B (TcdB) and binary toxin
CDT). Toxin A is a 308-kDa enterotoxin, toxin B is a 270-kDa
ytotoxin and binary toxin is an actin-speciﬁc ADP-ribosyl
ransferase. Toxin A and toxin B are encoded on the large
hromosomal region PaLoc that encompassed the two toxin
enes (tcdA and tcdB) and three additional genes for reg-
latory and transport functions (tcdC, tcdD and tcdE). The
inary toxin is encoded by the cdtA gene (enzymic compo-
ent) and the cdtB gene (binding component). These factors
re now identiﬁed by molecular methods.
The main laboratory diagnostic procedures for CDAD
nvolve cultivation of stool specimens on selective media
nd detection of toxin production by cell culture assays.
everal alternative tests are now available for diagnosis of
DAD, such as latex agglutination, immunoblotting, enzyme
mmunoassay and PCR. The introduction of typing meth-
ds such as PCR, ribotyping and PFGE to follow outbreaks
f CDAD in hospitals and communities has given important
pidemiological data. Real-time PCR to detect tcdA and
cdB genes directly from stool specimens is now available.
he emergence and spread of hypervirulent strains such as
I/NAP1/027 C. difﬁcile has made it mandatory to improve
apid laboratory diagnosis and investigate antibiotic resis-
ance mechanisms.
oi:10.1016/j.ijid.2008.05.099
4.003
reventing New and Recurrent CDAD
. Bartlett
Johns Hopkins University, Baltimore, MD, USA
here are three major risk factors: Advanced age, hospital-
zation or residence in a chronic care facility and exposure
o an antibacterial agent. Principles of prevention:
Antibiotic exposure:Low risk: Urinary antiseptics, sulfonamides, vancomycin,
metronidazole, tetracyclines, narrow spectrum betalac-
tams, macrolides, linezolid, ketolides, TMP-SMX
‘‘Big 3’’: Broad spectrum cephalosporins, ﬂuoro-
quinolones and clindamycin
